In the context of preventive examinations against cancer, EOPYY integrates into the Electronic Prescribing System “Diagnostic Tests of Oncological Biomarkers to check the presence of BRCA 1/2 gene mutations”.
According to an announcement by the Ministry of Health, after the successful completion of the work of the Committee for Negotiation of Fees and Prices of Medical Technological Products and the unanimous decision of the Board of Directors of EOPYY, the access and immediate service of patients to modern specialized diagnostic tests that contribute to obtaining optimal and individualized treatment decisions.
Control and monitoring through these tests concerns:
1. All women diagnosed with epithelial ovarian cancer, regardless of age and family history,
2. All women diagnosed with breast cancer before the age of 45,
3. All women who have been diagnosed with breast Ca at any age and have at least two (2) cases from the same side of the family with a thorough diagnosis of breast, ovarian, pancreatic or prostate Ca with a Gleason score greater than or equal to 7 and
4. All women in whose family there is a known mutation of the BRCA 1/2 genes
By signing these contracts, the development of a network of contracted laboratories that meet very strict quality criteria for the performance of innovative genetic tests is achieved, as well as the direct access of the beneficiaries to reliable laboratories with the elimination of bureaucratic procedures, through the issuance of an electronic referral.
The BRCA 1/2 gene test concerns approximately 3,000 women per year and the estimated financial benefit for EOPYY, through the implementation of the agreement, is estimated at around half a million euros, in relation to the annual costs for this test to date.
The participation of E.O.P.Y.Y. beneficiaries for the BRCA 1.2 test (NGS) it is set at 78.75 euros against the amount of 105 euros corresponding to 15% of the gazette price.When the execution of the complementary MLPA method is also required, the participation will be increased by 7.5 euros.
The Minister of Health Thanos Plevris said: “One more step in the effort of screening for serious diseases in our country is made with the inclusion in the prescription of genetic tests for Hereditary Cancer. For the first time, the insured will be able to do all the tests for the treatment of inherited cancer with less participation. The new test is a tool for cancer prevention.”
Read the News today and get the latest news.
Follow Skai.gr on Google News and be the first to know all the news.
As a seasoned news journalist, I bring a wealth of experience to the field. I’ve worked with world-renowned news organizations, honing my skills as a writer and reporter. Currently, I write for the sports section at News Bulletin 247, where I bring a unique perspective to every story.
